Peptide medicines are one of the fastest evolving areas of biotechnology, but behind every platform and every patent is a scientist committed to solving difficult problems.
Dr. Chengzao Sun is one of these scientists.
Today he is co-founder and chief scientific officer of Pinnacle Medicines. He leads research on macrocyclic oral peptide therapeutics. But his journey began long before the company was founded and his role as a manager.
It started in a chemistry lab.
Early Education and Scientific Foundation
Dr. Sun earned his Ph.D. in organic chemistry from Brown University. This training shaped his thinking.
Organic chemistry is detail-oriented. It requires precision. It rewards patience.
“Chemistry teaches you discipline,” he says. “If you miss one small detail, the whole molecule fails.”
This attitude was reflected in his career. He focused early on on peptide chemistry and synthesis methods. Peptides lie between small molecules and biologics. They are powerful but complex. For many years it was difficult to convert them into practical medicines.
This challenge attracted him.
“I’ve always liked problems that lie in the middle,” he explains. “Peptides are not simple. That’s why they are interesting.”
How Chengzao Sun built a career in peptide drug discovery
Over the past 20+ years, Dr. Sun worked in biotechnology and large pharmaceutical companies. His career includes roles at Amylin, Merck and Johnson & Johnson.
At each stop, the theme remained the same: the discovery of peptide drugs.
At Merck and Amylin, he worked on programs ranging from lead discovery to development. This meant designing molecules, testing their stability, and improving peptide binding to difficult biological targets.
He later took on a broader leadership position at Johnson & Johnson. He became head of the peptide platform and early portfolio.
This role wasn’t just science. It was a strategy.
“You don’t just ask whether a molecule works,” he says. “They wonder if this can become a drug.”
He led cross-functional teams. He worked with chemical, biological, clinical and regulatory groups. The programs progressed from early research to clinical phases 1, 2 and 3.
This change marked a turning point. He developed from a scientist to a scientific leader.
Why oral peptide therapeutics are important
Peptides are powerful. But many require an injection. This limits patient access and comfort.
Dr. Sun saw a gap.
“Peptides can achieve goals that small molecules cannot,” he explains. “But if patients don’t tolerate them easily, acceptance becomes more difficult.”
This problem shaped the vision behind Pinnacle Medicines.
Today, as co-founder and CSO, he leads research with a focus on macrocyclic and oral peptide platforms. Macrocyclic peptides are structured in such a way that they can improve stability and binding strength. The aim is to open up new therapeutic avenues.
His work spans multiple disease areas. These include immunology, oncology, cardiometabolic diseases and neuroscience.
He is also listed as an inventor on numerous patents related to peptide and macrocyclic therapeutics. Some focus on signaling pathways such as interleukin-23 (IL-23), a key player in inflammatory and autoimmune diseases.
“Oral peptides could be the ultimate solution,” he says. “It is safe, effective and convenient”
From Big Pharma to starting a business
Starting a company is different from running a department within a global pharmaceutical company.
At Pinnacle Medicines, Dr. Sun helps shape science and culture.
“In a smaller company, every decision counts,” he says. “You don’t hide behind structures. You build them.”
As CSO, he oversees research direction, platform development and scientific partnerships. He works closely with teams that drive programs from concept to early development.
The focus is not on speed as an end in itself. It is disciplined progress.
“Drug discovery takes time,” he says. “You have to respect the biology and we focus most on validated ones.”
Publications, Patents and Industry Impact
Dr. Sun is an author and co-author of peer-reviewed publications. His work includes advances in cyclic peptide linker design and molecular modeling.
He is also the inventor of several patents. These patents reflect years of applied research. These are not theoretical exercises. They are tied to real programs and real therapeutic goals.
His expertise lies at the interface between medicinal chemistry, peptide engineering and translational development.
In addition to his corporate work, he is a member of the scientific advisory board of the Boulder Peptide Society. The organization brings together researchers focused on peptide science and innovation.
“Science advances faster when people share ideas,” he says. “Community is important.”
Leadership style and industry perspective
Dr. Sun doesn’t describe himself as a visionary. He describes himself as practical.
“You gain credibility molecule by molecule,” he says.
Colleagues know him for connecting detailed chemistry with business strategy. This combination is important in biotechnology. A platform must function scientifically. But it also has to fit the development reality.
He believes the peptide space is entering a new phase.
“We have better tools now,” he says. “Computer-aided design. Improved synthesis. Better deployment strategies. The field is more mature.”
Nevertheless, he remains cautious.
“Drug discovery is humbling,” he says. “You learn to stay curious.”
The big picture of peptide innovation
The discovery of peptide drugs is no longer a niche. It is a highly competitive and rapidly evolving sector within biotechnology.
Leaders like Dr. Chengzao Sun helped set up the foundation in the early stages. Now they are shaping their next chapter.
His career shows steady progression: chemist, drug development scientist, platform leader, co-founder.
Each step builds on the last.
“I never chased a title,” he says. “I pursued difficult scientific questions.”
These questions are still being addressed at Pinnacle Medicines today.
And the molecules are still at the center of the story.
